Director Ilan Ganot linked sale of 7,205 Solid Biosciences (SLDB) shares disclosed

Rhea-AI Filing Summary

Solid Biosciences Inc. director Ilan Ganot reported an indirect sale of 7,205 shares of common stock on February 4, 2026 at a weighted average price of $6.4419 per share. The shares were held through his spouse and sold to cover withholding taxes after previously granted restricted stock units vested, under a durable automatic sell-to-cover instruction, so the transaction was not a discretionary trade.

Following this transaction, Ganot is reported as beneficially owning 25,271 shares indirectly through his wife, 99,297 shares directly (including shares held individually and jointly with Annie Ganot), and 19,394 shares indirectly through the Ilan Ganot 2017 Irrevocable Trust.

Insider Trade Summary

Net Seller: 7,205 shares ($46,414)

Net Sell 3 txns

Insider Ganot Ilan

Role Director

Sold 7,205 shs ($46K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,205	$6.4419	$46K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 25,271 shares (Indirect, Wife); Common Stock — 99,297 shares (Direct)

Footnotes (1)

1. This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. Represents 95,255 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ganot Ilan

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		S		7,205(1)	D	$6.4419(2)	25,271	I	Wife
Common Stock								99,297	D(3)
Common Stock								19,394	I	See Foonote 4(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

3. Represents 95,255 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.

4. Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.

	/s/ Kimberly Cornwell as attorney-in-fact for Ilan Ganot	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Ilan Ganot report for Solid Biosciences (SLDB)?

Ilan Ganot reported an indirect sale of 7,205 Solid Biosciences shares. The common stock sale occurred on February 4, 2026, at a weighted average price of $6.4419 per share, and the shares were held through his spouse as reported on the Form 4.

Why were 7,205 Solid Biosciences (SLDB) shares sold in this Form 4?

The 7,205 shares were sold to cover withholding taxes on vested restricted stock units. The transaction followed a durable automatic sales instruction adopted by Ms. Ganot, effecting a sell-to-cover election rather than a discretionary trade in the open market.

What price range was reported for the Solid Biosciences (SLDB) insider share sale?

The weighted average sale price was $6.4419 per share. According to the filing, the 7,205 shares were sold in multiple transactions at prices ranging from $6.28 to $6.60 per share, with detailed trade breakdowns available upon request.

How many Solid Biosciences (SLDB) shares does Ilan Ganot beneficially own after this transaction?

After the transaction, Ganot beneficially owns several blocks of SLDB shares. The filing reports 25,271 shares indirectly through his wife, 99,297 shares directly, and 19,394 shares indirectly via the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.

Is the reported Solid Biosciences (SLDB) share sale by Ilan Ganot discretionary?

No, the sale is described as non-discretionary. The filing explains it was executed under a durable automatic sales instruction letter adopted by Ms. Ganot to cover tax withholding on vested restricted stock units, rather than an opportunistic market-timing decision.

What is the relationship of the selling account to director Ilan Ganot at Solid Biosciences (SLDB)?

The sold shares were indirectly owned through Ganot’s spouse. The Form 4 lists the 7,205 shares as indirectly held with ownership described as “Wife,” reflecting spousal holdings that are attributed to him for reporting beneficial ownership.